Ascendis Pharma A/S (ASND)
Ascendis Pharma A/S Statistics
Share Statistics
Ascendis Pharma A/S has 59.84M shares outstanding. The number of shares has increased by 5.7% in one year.
| Shares Outstanding | 59.84M |
| Shares Change (YoY) | 5.7% |
| Shares Change (QoQ) | 0.14% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 59.38M |
| Failed to Deliver (FTD) Shares | 41 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 4.14M, so 6.88% of the outstanding shares have been sold short.
| Short Interest | 4.14M |
| Short % of Shares Out | 6.88% |
| Short % of Float | 8.29% |
| Short Ratio (days to cover) | 6.95 |
Valuation Ratios
The PE ratio is -20.36 and the forward PE ratio is 144.74. Ascendis Pharma A/S's PEG ratio is 0.86.
| PE Ratio | -20.36 |
| Forward PE | 144.74 |
| PS Ratio | 21.17 |
| Forward PS | 3.6 |
| PB Ratio | -72.81 |
| P/FCF Ratio | -25.02 |
| PEG Ratio | 0.86 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Ascendis Pharma A/S.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.17, with a Debt / Equity ratio of -8.1.
| Current Ratio | 1.17 |
| Quick Ratio | 0.84 |
| Debt / Equity | -8.1 |
| Debt / EBITDA | -2.95 |
| Debt / FCF | -2.78 |
| Interest Coverage | -4.26 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $357.56K |
| Profits Per Employee | $-371.76K |
| Employee Count | 1,017 |
| Asset Turnover | 0.31 |
| Inventory Turnover | 0.15 |
Taxes
| Income Tax | 4.84M |
| Effective Tax Rate | -1.3% |
Stock Price Statistics
The stock price has increased by 21.12% in the last 52 weeks. The beta is 0.54, so Ascendis Pharma A/S's price volatility has been higher than the market average.
| Beta | 0.54 |
| 52-Week Price Change | 21.12% |
| 50-Day Moving Average | 155.01 |
| 200-Day Moving Average | 138.24 |
| Relative Strength Index (RSI) | 65.77 |
| Average Volume (20 Days) | 519.9K |
Income Statement
In the last 12 months, Ascendis Pharma A/S had revenue of 363.64M and earned -378.08M in profits. Earnings per share was -6.53.
| Revenue | 363.64M |
| Gross Profit | 319.38M |
| Operating Income | -278.76M |
| Net Income | -378.08M |
| EBITDA | -290.02M |
| EBIT | -307.74M |
| Earnings Per Share (EPS) | -6.53 |
Balance Sheet
The company has 559.54M in cash and 856.62M in debt, giving a net cash position of -297.07M.
| Cash & Cash Equivalents | 559.54M |
| Total Debt | 856.62M |
| Net Cash | -297.07M |
| Retained Earnings | 0 |
| Total Assets | 1.18B |
| Working Capital | 153M |
Cash Flow
In the last 12 months, operating cash flow was -306.2M and capital expenditures -1.43M, giving a free cash flow of -307.62M.
| Operating Cash Flow | -306.2M |
| Capital Expenditures | -1.43M |
| Free Cash Flow | -307.62M |
| FCF Per Share | -5.31 |
Margins
Gross margin is 87.83%, with operating and profit margins of -76.66% and -103.97%.
| Gross Margin | 87.83% |
| Operating Margin | -76.66% |
| Pretax Margin | -102.64% |
| Profit Margin | -103.97% |
| EBITDA Margin | -79.76% |
| EBIT Margin | -76.66% |
| FCF Margin | -84.6% |
Dividends & Yields
ASND does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ASND is $200, which is 17.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $200 |
| Price Target Difference | 17.1% |
| Analyst Consensus | Buy |
| Analyst Count | 15 |
Scores
| Altman Z-Score | 4.33 |
| Piotroski F-Score | 4 |